Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292484 · ClinicalTrials.gov registry record · Phase 3
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
A Phase 3 study, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 911
- Enrollment target
NCT03292484 is a Phase 3 study that has completed, run by Aimmune Therapeutics. The registered enrollment target is 911 participants.
The verdict
NCT03292484, a Phase 3 study, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 911 participants
- Enrollment target
Study Summary
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
Interventions
- BIOLOGICAL AR101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03292484
The ClinicalTrials.gov registry entry for NCT03292484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 911 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AR101 is the first listed.
NCT03292484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03292484 about?
NCT03292484 is a clinical study titled "Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)". The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
What is the current status of trial NCT03292484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 911 participants. The study started on 2017-11-02. Estimated completion is 2023-04-27.
What interventions are being tested in trial NCT03292484?
The interventions under investigation include: AR101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03292484?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.